Galmed Pharmaceuticals Ltd.
GLMD
$4.63
$0.8121.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 993.00K | 684.00K | 946.00K | 1.01M | 1.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.78M | 2.04M | 3.04M | 2.10M | 2.11M |
| Operating Income | -2.78M | -2.04M | -3.04M | -2.10M | -2.11M |
| Income Before Tax | -2.72M | -1.91M | -4.82M | -1.89M | -2.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.72M | -1.91M | -4.82M | -1.89M | -2.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.72M | -1.91M | -4.82M | -1.89M | -2.50M |
| EBIT | -2.78M | -2.04M | -3.04M | -2.10M | -2.11M |
| EBITDA | -- | -- | -3.02M | -2.07M | -2.09M |
| EPS Basic | -2.86 | -2.32 | -6.41 | -2.77 | -5.06 |
| Normalized Basic EPS | -1.79 | -1.45 | -2.32 | -1.73 | -2.49 |
| EPS Diluted | -2.86 | -2.32 | -6.41 | -2.77 | -5.06 |
| Normalized Diluted EPS | -1.79 | -1.45 | -2.32 | -1.73 | -2.49 |
| Average Basic Shares Outstanding | 952.20K | 823.90K | 751.90K | 682.60K | 493.50K |
| Average Diluted Shares Outstanding | 952.20K | 823.90K | 751.90K | 682.60K | 493.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |